← Leaderboards
Hesham M Amin
University Of Tx Md Anderson Can Ctr
$3,011,396
Attributed
$4,998,219
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $711.2K · FY2006–25$1M$750K$500K$250K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,998,219 · 3
By mechanism
R01$4,589,979 · 2
K08$408,240 · 1
Top collaborators
- Dan Gabriel Duda5 shared
- Ahmed Kaseb5 shared
Most similar at University Of Tx Md Anderson Can Ctr
Same institution · by research overlap
- David Fuentes$1,768,670
- Eugene J Koay$2,020,718
- Ahmed Kaseb$3,699,074
- Chun Li$8,657,872
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsMalignant NeoplasmsRegimenCytokineSpecimenPathway InteractionsResponseT-LymphocyteBaseTumorSurvival RateAnaplastic Lymphoma KinaseNucleophosminAffectLymphomaNovel TherapeuticsOncogenicInhibitor/AntagonistChromosomal TranslocationChromosomesInsightGenesCell Cycle ArrestAgar
Grant awards (13)
A Phase II and Biomarker Study of Dual VEGF/PD-L1 Blockade in Neoadjuvant Setting in Resectable HCC Patients$461,706
R01 · FY2025 · CA
A Phase II and Biomarker Study of Dual VEGF/PD-L1 Blockade in Neoadjuvant Setting in Resectable HCC Patients$590,031
R01 · FY2024 · CA
A Phase II and Biomarker Study of Dual VEGF/PD-L1 Blockade in Neoadjuvant Setting in Resectable HCC Patients$608,666
R01 · FY2023 · CA
A Phase II and Biomarker Study of Dual VEGF/PD-L1 Blockade in Neoadjuvant Setting in Resectable HCC Patients$608,661
R01 · FY2022 · CA
A Phase II and Biomarker Study of Dual VEGF/PD-L1 Blockade in Neoadjuvant Setting in Resectable HCC Patients$711,171
R01 · FY2021 · CA
Role of IGF-IR tyrosine kinase in NPM-ALK-expressing T-cell lymphoma$327,850
R01 · FY2015 · CA · contact PI
Role of IGF-IR tyrosine kinase in NPM-ALK-expressing T-cell lymphoma$318,015
R01 · FY2014 · CA · contact PI
Role of IGF-IR tyrosine kinase in NPM-ALK-expressing T-cell lymphoma$308,179
R01 · FY2013 · CA · contact PI
Role of IGF-IR tyrosine kinase in NPM-ALK-expressing T-cell lymphoma$327,850
R01 · FY2012 · CA · contact PI
Role of IGF-IR tyrosine kinase in NPM-ALK-expressing T-cell lymphoma$327,850
R01 · FY2011 · CA · contact PI
Role of Jak3 in Anaplastic Large Cell Lymphoma$136,080
K08 · FY2008 · CA · contact PI
Role of Jak3 in Anaplastic Large Cell Lymphoma$136,080
K08 · FY2007 · CA · contact PI
Role of Jak3 in Anaplastic Large Cell Lymphoma$136,080
K08 · FY2006 · CA · contact PI